Physician profile
Julia Waters
NPI 1962140368
$1,731.79
in general payments reported to CMS, 2019-2025
14 companies · $930 in 2025
The $930 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $336 · 2024: $466 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $322.00 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $304.28 | 2024-2025 | |
| Glaxosmithkline, LLC. | $174.71 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $172.57 | 2025 | Voquezna |
| Exact Sciences Corporation | $156.91 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $140.96 | 2024-2025 | Airsupra, Breztri |
| Pfizer INC. | $100.43 | 2023-2025 | |
| Amgen INC. | $86.57 | 2024-2025 | Repatha, Otezla, Repatha |
| Insulet Corporation | $81.43 | 2024-2025 | Omnipod |
| Dexcom, INC. | $48.79 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $45.32 | 2023 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $37.92 | 2023 | Yupelri |
| Paratek Pharmaceuticals, INC. | $37.03 | 2024 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.87 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.